{"title":"Vafidemstat: a lysine-specific demethylase 1A inhibitor that shows promise for treating neuropsychiatric disorders.","authors":"Jacob Peedicayil, Dennis R Grayson","doi":"10.1080/28361512.2025.2552947","DOIUrl":null,"url":null,"abstract":"<p><p>The enzyme KDM1A encoded by <i>KDM1A</i> and also known as lysine-specific demethylase 1 (LSD1) plays important roles in the development and function of the brain. Vafidemstat is a KDM1A inhibitor that has shown beneficial effects in preclinical and clinical trials for the treatment of neuropsychiatric disorders, including borderline personality disorder (BPD), autism spectrum disorder (ASD), and attention-deficit hyperactivity disorder (ADHD). This article reviews available preclinical and clinical data on the use of vafidemstat in the treatment of these disorders. Vafidemstat appears to be a potential new and safe drug for the treatment of these disorders.</p>","PeriodicalId":520309,"journal":{"name":"Epigenetics reports","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12577760/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenetics reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/28361512.2025.2552947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The enzyme KDM1A encoded by KDM1A and also known as lysine-specific demethylase 1 (LSD1) plays important roles in the development and function of the brain. Vafidemstat is a KDM1A inhibitor that has shown beneficial effects in preclinical and clinical trials for the treatment of neuropsychiatric disorders, including borderline personality disorder (BPD), autism spectrum disorder (ASD), and attention-deficit hyperactivity disorder (ADHD). This article reviews available preclinical and clinical data on the use of vafidemstat in the treatment of these disorders. Vafidemstat appears to be a potential new and safe drug for the treatment of these disorders.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
